Recent Updates
Recently added Catalysts
MOLN Positive Sentiment

Molecular Diagnostics Collaboration and Licensing Deals Analysis Report 2024 with Directory of 740 Agreements Signed Since 2019

Key Takeaway: ResearchAndMarkets.com has released a new report titled "Molecular Diagnostics Collaboration and Licensing Deals 2016-2024," offering comprehensive insights into 740 agreements made since 2016. The report outlines significant trends in molecular diagnostics deals, emphasizing terms such as financials, collaboration specifics, and the responsibilities of partner companies. Additionally, it includes a directory of deals organized by various factors and aims to streamline the due diligence process for stakeholders in the biopharma industry. This updated resource will assist companies in analyzing past agreements to guide future collaborations.
Price reaction · baseline $3.61 (2024-05-06 close) · hit after-hours · clean, no other MOLN news in the window
day 0 close
+1.1%
day 1
+4.2%
day 3
+5.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Comprehensive report covering 740 molecular diagnostics deals.
  • Offers insights into financial terms and contract structures.
  • Includes a directory organized by company, deal type, and therapy area.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+104%
120-day peak, hindsight
Typical move
8.3%
average across 2 past catalysts
Lead asset
ensovibep
Phase 2 · Covid19

Full Press Release Details

Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Molecular Diagnostics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the molecular diagnostics deals entered into by the world's leading biopharma companies. Fully revised and updated, the report provides details of molecular diagnostics deals from 2016 to 2024.
The report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 740 molecular diagnostics deals announced since 2016 including financial terms where available including links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The report also includes numerous table and figures that illustrate the trends and activities in molecular diagnostics deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Understand deal trends since 2016
Browse molecular diagnostics collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Analyzing contract agreements allows due diligence of:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Chapter 1 - Introduction
Chapter 2 - Trends in molecular diagnostics dealmaking
2.2. Molecular diagnostics deals over the years
2.3. Most active molecular diagnostics dealmakers
2.4. Molecular diagnostics deals by deal type
2.5. Molecular diagnostics deals by therapy area
2.6. Molecular diagnostics deals by industry sector
2.7. Deal terms for molecular diagnostics deals
2.7.1 Molecular diagnostics deals headline values
2.7.2 Molecular diagnostics deal upfront payments
2.7.3 Molecular diagnostics deal milestone payments
2.7.4 Molecular diagnostics royalty rates
Chapter 3 - Leading molecular diagnostics deals
3.2. Top molecular diagnostics deals by value
Chapter 4 - Most active molecular diagnostics dealmakers
4.2. Most active molecular diagnostics dealmakers
4.3. Most active molecular diagnostics deals company profiles
Chapter 5 - Molecular diagnostics contracts dealmaking directory
5.2. Molecular diagnostics contracts dealmaking directory
Chapter 6 - Molecular diagnostics dealmaking by technology type
Deal directory - Molecular diagnostics deals by company A-Z
Deal directory - Molecular diagnostics deals by deal type
Deal directory - Molecular diagnostics deals by therapy area
Deal type definitions
Molecular diagnostics deals since 2016
Active molecular diagnostics dealmaking activity - 2016-2024
Molecular diagnostics deals by deal type since 2016
Molecular diagnostics deals by therapy area since 2016
Molecular diagnostics deals by industry sector since 2016
Molecular diagnostics deals with a headline value
Molecular diagnostics deals with an upfront value
Molecular diagnostics deals with a milestone value
Molecular diagnostics deals with a royalty rate value
Top molecular diagnostics deals by value since 2016
Most active molecular diagnostics dealmakers 2016-2024
Molecular diagnostics deals by technology type since 2016
For more information about this report visit https://www.researchandmarkets.com/r/k61zad
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Frequently Asked Questions

What does the report on molecular diagnostics cover?

The report details molecular diagnostics deals from 2016 to 2024, including R&D collaborations and outcomes commercialization.

How many molecular diagnostics deals are listed in the report?

The report contains a comprehensive listing of 740 molecular diagnostics deals announced since 2016.

What financial information is included in the report?

The report includes financial terms like upfront payments, milestone payments, and royalty rates.

How can the report assist in deal due diligence?

It allows detailed analysis of contract agreements, including rights granted, payment structures, and key terms.

Where can I access contract documents for the deals?

The report provides links to online deal records and contract documents when available.

Last updated: May 7, 2024